Objective:

To explore the mechanisms of action of consolidation radiotherapy following first-line immunotherapy combined with chemotherapy in patients with stage IV esophageal squamous cell carcinoma (ESCC) and analyze its feasibility and implementation strategies.

Approach:

Key Findings:

• Esophageal cancer has a high incidence and mortality rate, particularly in advanced stages, with squamous cell carcinoma being the predominant type in China.
• Immunotherapy combined with chemotherapy has improved survival rates in stage IV ESCC, but local control remains suboptimal for some patients.

Interpretation:

The addition of consolidation radiotherapy could potentially address the issue of local recurrence in patients receiving immunotherapy combined with chemotherapy for stage IV ESCC.

Limitations:

• No large-scale clinical studies have demonstrated the efficacy of radiotherapy in achieving local control for stage IV esophageal cancer under the current treatment regimen.

Conclusion:

The paper discusses the feasibility of adjuvant radiotherapy following first-line chemotherapy combined with immunotherapy for stage IV esophageal cancer patients.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.